Hotaling Investment Management LLC lowered its stake in Johnson & Johnson (NYSE:JNJ – Get Rating ) by 24.9% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,198 shares of the company’s stock after selling 14,298 shares during the quarter. Johnson & Johnson makes up 2.9% of Hotaling Investment Management LLC’s investment portfolio, making the stock its 5th biggest holding. Hotaling Investment Management LLC’s holdings in Johnson & Johnson were worth $7,656,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. Edge Wealth Management LLC boosted its position in Johnson & Johnson by 0.7% during the 4th quarter. Edge Wealth Management LLC now owns 86,628 shares of the company’s stock valued at $14,819,000 after acquiring an additional 584 shares during the period. Johanson Financial Advisors Inc. raised its holdings in Johnson & Johnson by 3.1% in the fourth quarter. Johanson Financial Advisors Inc. now owns 25,921 shares of the company’s stock worth $4,434,000 after purchasing an additional 778 shares during the last quarter. Bogart Wealth LLC boosted its position in Johnson & Johnson by 11.7% in the fourth quarter. Bogart Wealth LLC now owns 22,868 shares of the company’s stock valued at $3,912,000 after buying an additional 2,403 shares during the period. Welch & Forbes LLC raised its position in Johnson & Johnson by 1.3% in the 4th quarter. Welch & Forbes LLC now owns 789,375 shares of the company’s stock valued at $135,038,000 after buying an additional 10,063 shares during the period. Finally, Wolf Group Capital Advisors boosted its position in Johnson & Johnson by 206.4% in the 4th quarter. Wolf Group Capital Advisors now owns 78,831 shares of the company’s stock valued at $13,486,000 after purchasing an additional 53,101 shares during the period. 68.78% of the shares are currently owned by hedge funds and other institutional investors.
In related news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares in the company, valued at $12,336,803. The transaction was disclosed in a filing with the Securities and Exchange Commission, which is available on the SEC’s website. Also, insider William Hait sold 29,699 shares of the company’s stock in a transaction dated Thursday, April 21st. The shares were sold at an average price of $183.58, for a total value of $5,452,142.42. Following the completion of the sale, the insider now owns 80,236 shares of the company’s stock, valued at approximately $14,729,724.88. Disclosure for this sale can be found here. Insiders sold 78,161 shares of company stock valued at $13,895,302 in the last quarter. 0.35% of shares are currently owned by corporate insiders.
A number of analysts have weighed in on JNJ shares. Daiwa Capital Markets began coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Citigroup decreased their price objective on Johnson & Johnson from $210.00 to $205.00 in a research note on Tuesday, May 17th. Morgan Stanley boosted their price objective on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Friday. Goldman Sachs Group boosted their price objective on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Finally, Raymond James boosted their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Moderate Buy” and an average price target of $190.67, according to data from MarketBeat.com.
Shares of JNJ stock opened at $178.35 on Tuesday. The company has a quick ratio of 1.14, a current ratio of 1.39, and a debt-to-equity ratio of 0.39. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The firm has a market capitalization of $469.31 billion, a PE ratio of 24.04, a price-to-earnings-growth ratio of 3.53 and a beta of 0.63. The stock’s fifty-day simple moving average is $176.89, and its 200-day simple moving average is $174.21.
Johnson & Johnson (NYSE:JNJ – Get Rating ) last issued its quarterly earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.60 by $0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The business had revenue of $23.43 billion for the quarter, compared to analyst estimates of $23.62 billion. During the same quarter a year ago, the firm posted $2.59 earnings per share. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. analysts predict that Johnson & Johnson will post 10.23 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were paid a dividend of $1.13 per share. This represents an annual dividend of $4.52 and a dividend yield of 2.53%. The ex-dividend date was Monday, May 23rd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s dividend payout ratio is 60.92%.
Johnson & Johnson Profile (Get rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various products in the field of health care worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Get the Rating ).
Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com ‘s FREE daily email newsletter.